Positive pre-IND meeting with FDA for new ovarian cancer cell therapy

Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has completed a pre-investigational new drug (pre-IND) meeting with the FDA for a phase 1/2 clinical trial of its cell therapy product, CTH-401 for the treatment of ovarian cancer.

Related Keywords

, Alan Trounson , Investigational New Drug , Bio Developments , Markets Amp Regulations , Cell Amp Gene Therapies , Ovarian Cancer , Dancer , Ncology , Cell And Gene Therapy , Cell Therapy ,